# EDGAR Filing Document

**Accession Number:** 0001750284
**File Stem:** 0001193125-25-286716
**Filing Date:** 2025-11
**Character Count:** 13770
**Document Hash:** a9aa4da1e687193ef8547bd3f343e4e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-286716.hdr.sgml**: 20251118

**ACCESSION NUMBER**: 0001193125-25-286716

**CONFORMED SUBMISSION TYPE**: S-3MEF

**PUBLIC DOCUMENT COUNT**: 13

**FILED AS OF DATE**: 20251118

**DATE AS OF CHANGE**: 20251118

**EFFECTIVENESS DATE**: 20251118

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Olema Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001750284
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 300409740
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-3MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291636
- **FILM NUMBER:** 251496533

**BUSINESS ADDRESS:**
- **STREET 1:** 780 BRANNAN STREET
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94103
- **BUSINESS PHONE:** (415) 651-3316

**MAIL ADDRESS:**
- **STREET 1:** 780 BRANNAN STREET
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94103

**As filed with the Securities and Exchange Commission on November 18, 2025** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-3**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## OLEMA PHARMACEUTICALS, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **30-0409740** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

**780 Brannan Street** 

**San Francisco, California 94103** 

**(415) 651-3316** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Sean Bohen, M.D., Ph.D.** 

**Chief Executive Officer and President** 

**780 Brannan Street** 

**San Francisco, California 94103** 

**(415) 651-3316** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | |
|:---|:---|
| **Shane Kovacs**<br> **Chief Operating and Financial Officer**<br> **780 Brannan Street**<br> **San Francisco, California 94103**<br> **(415) 651-3316** | **Yvan-Claude Pierre**<br> **Kristin VanderPas**<br> **Julia Boesch**<br> **Cooley LLP**<br> **3 Embarcadero Center, 20th Floor**<br> **San Francisco, California 94111**<br> **(415) 693-2000** |

---

**Approximate date of commencement of proposed sale to the public:** From time to time after this registration statement becomes effective.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ☒ 333-284146

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The Registration Statement shall become effective upon filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended.** 

------

**EXPLANATORY NOTE AND INCORPORATION OF** 

**CERTAIN INFORMATION BY REFERENCE** 

Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, Olema Pharmaceuticals, Inc. (the "Registrant") is filing this Registration Statement on Form S-3 (this "Registration Statement") with the Securities and Exchange Commission (the "Commission"). This Registration Statement relates to the public offering of securities contemplated by the Registration Statement on Form S-3 (File No. 333-284146) (the "Prior Registration Statement"), which the Registrant filed with the Commission on January 6, 2025, and which the Commission declared effective on January 15, 2025.

The Registrant is filing this Registration Statement for the sole purpose of increasing the aggregate amount of securities offered by the Registrant by a proposed aggregate offering price of $40,000,000, which includes shares that may be sold by the Registrant in the event the underwriters exercise their option to purchase additional shares of the Registrant's common stock. The additional securities that are being registered for issuance and sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price of unsold securities under the Prior Registration Statement. The information set forth in the Prior Registration Statement and all exhibits to the Prior Registration Statement are hereby incorporated by reference into this Registration Statement.

The required opinion and consents are listed on the Exhibit Index below and filed herewith or incorporated by reference herein.

------

**PART II** 

**INFORMATION NOT REQUIRED IN PROSPECTUS** 

**Item 16. Exhibits.** 

(a) Exhibits. All exhibits filed with or incorporated by reference in the Registration Statement on Form S-3 (File No. 333-284146) are incorporated by reference into, and shall be deemed a part of, this Registration Statement, and the following additional exhibits are filed
herewith, as part of this Registration Statement:

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 5.1 | [Opinion of Cooley LLP (incorporated by reference to Exhibit 5.1 to the Prior Registration Statement).](http://www.sec.gov/Archives/edgar/data/1750284/000119312525002157/d901834dex51.htm) |
| 23.1 | [Consent of Independent Registered Public Accounting Firm.](d35199dex231.htm) |
| 23.2 | [Consent of Cooley LLP (included in Exhibit 5.1).](http://www.sec.gov/Archives/edgar/data/1750284/000119312525002157/d901834dex51.htm) |
| 24.1 | [Powers of Attorney (incorporated by reference to Exhibit 24.1 to the Prior Registration Statement).](http://www.sec.gov/Archives/edgar/data/1750284/000119312525002157/d901834ds3.htm#sig) |
| 107 | [Filing Fee Table.](d35199dexfilingfees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on November 18, 2025.

---

| | |
|:---|:---|
| **OLEMA PHARMACEUTICALS, INC.** | **OLEMA PHARMACEUTICALS, INC.** |
| By: | */s/ Sean Bohen* |
|  | Sean Bohen, M.D., Ph.D. |
|  | President and Chief Executive Officer |

---

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Sean Bohen*<br> Sean Bohen, M.D., Ph.D. | President, Chief Executive Officer and Director<br> (Principal Executive Officer) | November 18, 2025 |
| */s/ Shane Kovacs*<br> Shane Kovacs | Chief Operating and Financial Officer<br> (Principal Financial Officer and Principal Accounting Officer) | November 18, 2025 |
| */s/ Ian Clark\**<br> Ian Clark | Chairperson of the Board | November 18, 2025 |
| */s/ Cynthia Butitta\**<br> Cynthia Butitta, Ph.D. | Director | November 18, 2025 |
| */s/ Scott Garland\**<br> Scott Garland | Director | November 18, 2025 |
| */s/ Cyrus L. Harmon, Ph.D.\**<br> Cyrus L. Harmon, Ph.D. | Director | November 18, 2025 |
| */s/ Sandra Horning, M.D.\**<br> Sandra Horning, M.D. | Director | November 18, 2025 |
| */s/ Gorjan Hrustanovic, Ph.D.\**<br> Gorjan Hrustanovic, Ph.D. | Director | November 18, 2025 |
| */s/ Yi Larson\**<br> Yi Larson | Director | November 18, 2025 |
| */s/ Andrew Rappaport\**<br> Andrew Rappaport | Director | November 18, 2025 |
| */s/ Graham Walmsley, M.D., Ph.D.\**<br> Graham Walmsley, M.D., Ph.D. | Director | November 18, 2025 |

---

---

| | |
|:---|:---|
| \*By: | */s/ Shane Kovacs* |
|  | Shane Kovacs |
|  | *Attorney-in-fact* |

---

## Exhibit 23.1

**EXHIBIT 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement on this Form S-3 filed pursuant to Rule 462(b) of the Securities Act of 1933 of reference to our firm under the caption "Experts" and to the incorporation by reference of our report dated March 18, 2025, with respect to the consolidated financial statements of Olema Pharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Iselin, New Jersey

November 18, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-3**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Olema Pharmaceuticals, Inc.**  |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Security Type**  | **Security Class Title**  | **Fee Calculation or Carry Forward Rule**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
|  |  | Equity | Common Stock, par value $0.0001 per share | 457(o) |  |  |  |
|  |  | Other | Warrants | 457(o) |  |  |  |
| Fees to be Paid | 1 | Unallocated (Universal) Shelf |  | 457(o) | $40000000.00 | 0.0001381 | $5524.00 |
| Fees Previously Paid |  |  |  |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |
|  |  |  | Total Offering Amounts: | Total Offering Amounts: | $40000000.00  |  | $5524.00  |
|  |  |  | Total Fees Previously Paid:  | Total Fees Previously Paid:  |  |  | $0.00  |
|  |  |  | Total Fee Offsets:  | Total Fee Offsets:  |  |  | $0.00  |
|  |  |  | Net Fee Due:  | Net Fee Due:  |  |  | $5524.00  |

---

 **Offering Note** <br>

<sup>1</sup> The Registrant previously registered the offer and sale of certain securities, including its common stock, par value $0.0001 per share, having a proposed maximum aggregate offering price of $200,000,000 pursuant to Registration Statement on Form S-3 (File No. 333-284146), which was filed on January 6, 2025 and declared effective by the SEC on January 15, 2025 (the "Prior Registration Statement"). As of the date hereof, a balance of $200,000,000 of such securities remains unsold under the Prior Registration Statement. In accordance with Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction IV(A) of Form S-3, the Registrant is hereby registering the offer and sale of an additional $40,000,000 of its shares of common stock. The additional amount of securities that is being registered for offer and sale represents no more than 20% of the maximum aggregate offering price of the remaining securities available to be sold under the Prior Registration Statement.

---

| | |
|:---|:---|
| | |
| **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Amount of Securities Previously Registered**  | **Maximum Aggregate Offering Price of Securities Previously Registered**  | **Form Type**  | **File Number**  | **Initial Effective Date**  |
| N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

---